Clinical trial
Total Hip Replacement Study With XRP4563 (Enoxaparin Sodium)
NCT00349180 · Sanofi, Industry · Completed
Key facts
| NCT number | NCT00349180 |
|---|---|
| Title | Total Hip Replacement Study With XRP4563 (Enoxaparin Sodium) |
| Official title | Multicenter, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Enoxaparin Sodium（RP54563）20mg qd and 20mg Bid for 14 Days in Patients With Total Hip Replacement |
| Lead sponsor | Sanofi, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Arthroplasty, Replacement, Hip |
| Intervention type | Drug |
| Interventions | Enoxaparin sodium |
| Enrollment | 156 |
| Start date | Jun 1, 2006 |
| First posted | Jul 6, 2006 |
| Last update posted | Mar 27, 2009 |
| Countries | Japan |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: